{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:31:09Z","timestamp":1793773869985,"version":"4.6.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360678"],"award-info":[{"award-number":["82360678"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118460","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T07:54:02Z","timestamp":1764834842000},"page":"118460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of novel 1-(4-aminophenylacetyl)piperidine derivatives as FXR partial agonists for the potential treatment of metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1016","volume":"303","author":[{"given":"Bing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghu","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-5483","authenticated-orcid":false,"given":"Xiangduan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118460_bib1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2025.118460_bib2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2025.118460_bib3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","article-title":"Integrative metabolism in MASLD and MASH: pathophysiology and emerging mechanisms","volume":"83","author":"Steinberg","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118460_bib4","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.cmet.2024.08.005","article-title":"SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation","volume":"36","author":"Liu","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2025.118460_bib5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118460_bib6","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s41564-023-01418-7","article-title":"Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid","volume":"8","author":"Wei","year":"2023","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2025.118460_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2021-324915","article-title":"Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002\u20132033: the ITA.LI.CA database","volume":"72","author":"Vitale","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2025.118460_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000352","article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013-2022: the dominance of metabolic dysfunction\u2013associated steatotic liver disease and alcohol-associated liver disease","volume":"8","author":"Younossi","year":"2024","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.ejmech.2025.118460_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118460_bib10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: october 2024 updates to AASLD practice guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2025.118460_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000670","article-title":"Early experience with resmetirom to treat metabolic dysfunction\u2013associated steatohepatitis with fibrosis in a real-world setting","volume":"9","author":"Ravela","year":"2025","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.ejmech.2025.118460_bib12","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.118460_bib13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118460_bib14","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.apsb.2024.02.011","article-title":"Bile acids and coronavirus disease 2019","volume":"14","author":"Huang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118460_bib15","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2025.118460_bib16","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2025.118460_bib17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00281-022-00935-7","article-title":"Bile acids and their receptors: modulators and therapeutic targets in liver inflammation","volume":"44","author":"Bertolini","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.ejmech.2025.118460_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118460_bib19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","article-title":"Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology","volume":"19","author":"Fuchs","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118460_bib20","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1021\/acs.jmedchem.5c00539","article-title":"Dual modulator of FXR and HSD17B13: revitalizing FXR therapies in MASH","volume":"68","author":"Wei","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118460_bib21","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1021\/acs.jmedchem.4c02720","article-title":"Discovery of First-in-Class FXR and HSD17B13 dual modulator for the treatment of metabolic dysfunction-associated Fatty liver disease","volume":"68","author":"Jiao","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118460_bib22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/ijms17040536","article-title":"Structural investigation for optimization of anthranilic acid derivatives as partial FXR agonists by in Silico approaches","volume":"17","author":"Chen","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118460_bib23","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3389\/fphar.2020.00590","article-title":"Repositioning an immunomodulatory drug vidofludimus as a farnesoid X receptor modulator with therapeutic effects on NAFLD","volume":"11","author":"Zhu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118460_bib24","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118460_bib25","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","article-title":"New and emerging treatments for metabolic dysfunction-associated steatohepatitis","volume":"36","author":"Tincopa","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2025.118460_bib26","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118460_bib27","doi-asserted-by":"crossref","first-page":"18873","DOI":"10.1038\/s41598-022-23539-5","article-title":"Effect of FXR agonist GW4064 in the treatment of hilar cholangiocarcinoma in rats","volume":"12","author":"Wang","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118460_bib28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpdd.762","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel non\u2013bile acid FXR agonist Tropifexor (LJN452) in healthy volunteers","volume":"9","author":"Badman","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejmech.2025.118460_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2025.118460_bib30","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.118460_bib31","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","article-title":"Farnesoid X receptor (FXR): structures and ligands","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ejmech.2025.118460_bib32","doi-asserted-by":"crossref","first-page":"9974","DOI":"10.1021\/acs.jmedchem.2c00641","article-title":"Discovery of (E)-3-(3-((2-Cyano-4\u2032-dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic acid methyl ester, an intestine-specific, FXR partial agonist for the treatment of nonalcoholic steatohepatitis","volume":"65","author":"Shim","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118460_bib33","first-page":"1","article-title":"Liver-distributed FXR agonist TERN-101 demonstrates favorable safety and efficacy profile in NASH phase 2a lift study","volume":"74","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2025.118460_bib34","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118460_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128026","article-title":"Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure\u2013activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism","volume":"41","author":"Gohda","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118460_bib36","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1113\/JP275236","article-title":"Ivermectin and its target molecules: shared and unique modulation mechanisms of ion channels and receptors by ivermectin","volume":"596","author":"Chen","year":"2018","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejmech.2025.118460_bib37","article-title":"Geniposidic acid targeting FXR \u201cS332 and H447\u201d mediated conformational change to upregulate CYPs and miR\u201019a\u20103p to ameliorate drug\u2010induced liver injury","volume":"12","author":"Fan","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2025.118460_bib38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.118460_bib39","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.cell.2024.02.034","article-title":"Flexible scaffold-based cheminformatics approach for polypharmacological drug design","volume":"187","author":"Chen","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118460_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115992","article-title":"Discovery of 4-aminophenylacetamide derivatives as intestine-specific farnesoid X receptor antagonists for the potential treatment of nonalcoholic steatohepatitis","volume":"264","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118460_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.118632","article-title":"Exploring the wound healing potential of Lobostemon fruticosus using in vitro and in vivo bioassays","volume":"336","author":"Kgosana","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2025.118460_bib42","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00010.2008","article-title":"Role of bile acids and bile acid receptors in metabolic regulation","volume":"89","author":"Lefebvre","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2025.118460_bib43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/md20040225","article-title":"Fucoxanthin attenuates free fatty acid-induced nonalcoholic fatty liver disease by regulating lipid metabolism\/oxidative stress\/inflammation via the AMPK\/Nrf2\/TLR4 signaling pathway","volume":"20","author":"Ye","year":"2022","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2025.118460_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115510","article-title":"Design, synthesis and anti-NASH effect evaluation of novel GFT505 derivatives in vitro and in vivo","volume":"257","author":"Xiang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118460_bib45","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.3390\/antiox11071391","article-title":"Taurine attenuates oxidized fish oil-induced oxidative stress and lipid metabolism disorder in mice","volume":"11","author":"Guo","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejmech.2025.118460_bib46","article-title":"Integrated lipidomics and metabolomics study of four chemically induced mouse models of acute intrahepatic cholestasis","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118460_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117284","article-title":"Design, synthesis, and biological evaluation of imidazolidinone derivatives as potent PPAR\u03b1\/\u03b4 agonists for the treatment of cholestatic liver diseases","volume":"286","author":"Fu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118460_bib48","doi-asserted-by":"crossref","first-page":"6908","DOI":"10.1038\/s41467-023-42702-8","article-title":"Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis","volume":"14","author":"Tschuck","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118460_bib49","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.3390\/nu13124343","article-title":"FXR, a key regulator of lipid metabolism, is inhibited by ER stress-mediated activation of JNK and p38 MAPK in large yellow croakers (Larimichthys crocea) fed high fat diets","volume":"13","author":"Du","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.ejmech.2025.118460_bib50","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bpj.2009.11.011","article-title":"Determination of ensemble-average pairwise root mean-square deviation from experimental B-Factors","volume":"98","author":"Kuzmanic","year":"2010","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejmech.2025.118460_bib51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.procbio.2023.12.014","article-title":"Docking and molecular dynamic simulations of Mithramycin-A and Tolfenamic acid against Sp1 and survivin","volume":"137","author":"Lambring","year":"2024","journal-title":"Process Biochem"},{"key":"10.1016\/j.ejmech.2025.118460_bib52","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/md21080446","article-title":"Experimental and computational investigation of solvatochromism, tautomerism and free energy landscapes of a pyridoacridinium Quaternary salt","volume":"21","author":"Gartshore","year":"2023","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2025.118460_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117663","article-title":"Design and synthesis of novel styrylquinolinium derivatives for the treatment of breast Cancer: targeting the c-Myc G-quadruplex","volume":"291","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118460_bib54","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17460441.2024.2349149","article-title":"Understanding the impact of binding free energy and kinetics calculations in modern drug discovery","volume":"19","author":"Adediwura","year":"2024","journal-title":"Expert. Opin. Drug. Discov."},{"key":"10.1016\/j.ejmech.2025.118460_bib55","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.ejmech.2025.118460_bib56","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A simple diet-and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"J. Hepatol"},{"key":"10.1016\/j.ejmech.2025.118460_bib57","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1021\/acs.jmedchem.2c02123","article-title":"Discovery of the first subnanomolar PPAR\u03b1\/\u03b4 dual agonist for the treatment of cholestatic liver diseases","volume":"66","author":"Feng","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118460_bib58","volume":"122","author":"Wang","year":"2024"},{"key":"10.1016\/j.ejmech.2025.118460_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107940","article-title":"Design, synthesis and FXR partial agonistic activity of anthranilic acid derivatives bearing aryloxy moiety as therapeutic agents for metabolic dysfunction-associated steatohepatitis","volume":"153","author":"Chen","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118460_bib60","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3390\/cells11182854","article-title":"Human allogeneic liver-derived progenitor cells significantly improve NAFLD activity score and fibrosis in late-stage NASH animal model","volume":"11","author":"Najimi","year":"2022","journal-title":"Cells"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:44:27Z","timestamp":1781325867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425012255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":60,"alternative-id":["S0223523425012255"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118460","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel 1-(4-aminophenylacetyl)piperidine derivatives as FXR partial agonists for the potential treatment of metabolic dysfunction-associated steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118460"}}